With the pandemic forcing big changes to the traditional approach for conducting clinical trials, many companies are adopting a decentralized trial strategy that steers clear of sites. Decentralized trials, of course, were on-the-rise even before the pandemic, boasting higher recruitment and retention rates for patients who prefer trials without the logistical challenges of in-clinic attendance. But we also know that taking a decentralized trial approach introduces new challenges for those companies hoping to ramp up an early phase trial or keep later stage studies going during the pandemic. Strengthening the direct-to-patient supply chain is crucial in ensuring the decentralized trial process goes smoothly for patient and company alike. We’ll discuss the challenges posed by direct-to-patient supply with decentralized trial experts offering solutions for common roadblocks.
You are here: / / Optimizing Direct-to-Patient Clinical Supply for Decentralized Clinical Trials